Amyloid beta-HSP60 peptide conjugate vaccine treats a mouse model of Alzheimer's disease

Anna Nemirovsky, Yair Fisher, Rona Baron, Irun R. Cohen, Alon Monsonego

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Active vaccination with amyloid beta peptide (Aβ) to induce beneficial antibodies was found to be effective in mouse models of Alzheimer's disease (AD), but human vaccination trials led to adverse effects, apparently caused by exuberant T-cell reactivity. Here, we sought to develop a safer active vaccine for AD with reduced T-cell activation. We treated a mouse model of AD carrying the HLA-DR DRB1*1501 allele, with the Aβ B-cell epitope (Aβ 1-15) conjugated to the self-HSP60 peptide p458. Immunization with the conjugate led to the induction of Aβ-specific antibodies associated with a significant reduction of cerebral amyloid burden and of the accompanying inflammatory response in the brain; only a mild T-cell response specific to the HSP peptide but not to the Aβ peptide was found. This type of vaccination, evoking a gradual increase in antibody titers accompanied by a mild T-cell response is likely due to the unique adjuvant and T-cell stimulating properties of the self-HSP peptide used in the conjugate and might provide a safer approach to effective AD vaccination.

Original languageEnglish
Pages (from-to)4043-4050
Number of pages8
Issue number23
StatePublished - 23 May 2011


  • Alzheimer's disease
  • Amyloid beta peptide
  • Heat shock protein (HSP)
  • Human leukocyte antigen (HLA)
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology (all)
  • Veterinary (all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases


Dive into the research topics of 'Amyloid beta-HSP60 peptide conjugate vaccine treats a mouse model of Alzheimer's disease'. Together they form a unique fingerprint.

Cite this